The DOI matches its Crossref record; 1,264 of the 1,264 references it cites were found in a registry or an index.
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Open accessAbstract
Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–400 of 1,264
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Exosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Senescence and the SASP: many therapeutic avenues
Birch, J., & Gil, J. (2020) · Genes & Development · doi:10.1101/gad.343129.120 · Cited by 1,177
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
Laberge, R.-M., Sun, Y., Orjalo, A. V., Patil, C. K., Freund, A., Zhou, L., Curran, S. C., Davalos, A. R., Wilson-Edell, K. A., Liu, S., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3195 · Cited by 1,160
Cellular senescence: the good, the bad and the unknown
Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L., & Lerman, L. O. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00601-z · Cited by 1,150
Zhu, Y., Tchkonia, T., Fuhrmann‐Stroissnigg, H., Dai, H. M., Ling, Y. Y., Stout, M. B., Pirtskhalava, T., Giorgadze, N., Johnson, K. O., Giles, C. B., et al. (2016) · Aging Cell · doi:10.1111/acel.12445 · Cited by 1,148
Circulating Tumor Cells: Liquid Biopsy of Cancer
Alix-Panabières, C., & Pantel, K. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.194258 · Cited by 1,134
Protection against Fatal Sindbis Virus Encephalitis by Beclin, a Novel Bcl-2-Interacting Protein
Liang, X. H., Kleeman, L. K., Jiang, H. H., Gordon, G., Goldman, J. E., Berry, G., Herman, B., & Levine, B. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8586-8596.1998 · Cited by 1,132
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Detection, clinical relevance and specific biological properties of disseminating tumour cells
Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2375 · Cited by 1,118
Park, J. E., Chen, H. H., Winer, J., Houck, K. A., & Ferrara, N. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47298-5 · Cited by 1,112
Senolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Global histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Waddington, C. H. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr184 · Cited by 1,082
p62 at the crossroads of autophagy, apoptosis, and cancer
Moscat, J., & Diaz-Meco, M. T. (2009) · Cell · doi:10.1016/j.cell.2009.05.023 · Cited by 1,073
BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis
McArthur, K., Whitehead, L. W., Heddleston, J. M., Li, L., Padman, B. S., Oorschot, V., Geoghegan, N. D., Chappaz, S., Davidson, S., San Chin, H., et al. (2018) · Science · doi:10.1126/science.aao6047 · Cited by 1,072
MULTIPLE FORMS OF ENZYMES: TISSUE, ONTOGENETIC, AND SPECIES SPECIFIC PATTERNS
Markert, C. L., & Møller, F. (1959) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.45.5.753 · Cited by 1,072
Lamin B1 loss is a senescence-associated biomarker
Freund, A., Laberge, R.-M., Demaria, M., & Campisi, J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-10-0884 · Cited by 1,046
BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death
Huang, D. C. S., & Strasser, A. (2000) · Cell · doi:10.1016/s0092-8674(00)00187-2 · Cited by 1,043
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Self-citationOncogenic roles of EMT-inducing transcription factors
Puisieux, A., Brabletz, T., & Caramel, J. (2014) · Nature Cell Biology · doi:10.1038/ncb2976 · Cited by 1,040
Huber, M. A., Azoitei, N., Baumann, B., Grünert, S., Sommer, A., Pehamberger, H., Kraut, N., Beug, H., & Wirth, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421358 · Cited by 1,033
Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis
Lu, W., & Kang, Y. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.010 · Cited by 1,030
Kahlert, C., Melo, S. A., Protopopov, A., Tang, J., Seth, S., Koch, M., Zhang, J., Weitz, J., Chin, L., Futreal, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.c113.532267 · Cited by 1,026
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
The role of BCL-2 family proteins in regulating apoptosis and cancer therapy
Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.985363 · Cited by 1,011
Circulating tumor cells: biology and clinical significance
Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., Zhu, F., Zhou, D., Zheng, S., Chen, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00817-8 · Cited by 993
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Vande Woude, G. F. (1984) · Nature · doi:10.1038/311029a0 · Cited by 989
Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3513 · Cited by 975
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Navigating the DNA methylation landscape of cancer
Nishiyama, A., & Nakanishi, M. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.05.002 · Cited by 972
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 970
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Kucharzewska, P., Christianson, H. C., Welch, J. E., Svensson, K. J., Fredlund, E., Ringnér, M., Mörgelin, M., Bourseau-Guilmain, E., Bengzon, J., & Belting, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220998110 · Cited by 939
Liquid biopsy: current technology and clinical applications
Nikanjam, M., Kato, S., & Kurzrock, R. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01351-y · Cited by 931
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0052-4 · Cited by 928
Targeting Autophagy in Cancer: Recent Advances and Future Directions
Amaravadi, R. K., Kimmelman, A. C., & Debnath, J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0292 · Cited by 928
Death by TNF: a road to inflammation
van Loo, G., & Bertrand, M. J. M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00792-3 · Cited by 926
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
Lactate modulation of immune responses in inflammatory versus tumour microenvironments
Certo, M., Tsai, C.-H., Pucino, V., Ho, P.-C., & Mauro, C. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0406-2 · Cited by 924
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Zong, W.-X., & Thompson, C. B. (2006) · Genes & Development · doi:10.1101/gad.1376506 · Cited by 917
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Lee, Y.-R., Chen, M., & Pandolfi, P. P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0015-0 · Cited by 917
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Goonetilleke, K. S., & Siriwardena, A. K. (2007) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2006.10.004 · Cited by 877
The Role of Snail in EMT and Tumorigenesis
Wang, Y., Shi, J., Chai, K., Ying, X., & Zhou, B. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113136660102 · Cited by 875
Exosome-based liquid biopsies in cancer: opportunities and challenges
Yu, W., Hurley, J., Roberts, D., Chakrabortty, S. K., Enderle, D., Noerholm, M., Breakefield, X. O., & Skog, J. K. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.074 · Cited by 870
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Moerlooze, L. D., Spencer-Dene, B., Revest, J.-M., Hajihosseini, M., Rosewell, I., & Dickson, C. (2000) · Development · doi:10.1242/dev.127.3.483 · Cited by 864
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Self-citationAutophagy-Independent Functions of the Autophagy Machinery
Galluzzi, L., & Green, D. R. (2019) · Cell · doi:10.1016/j.cell.2019.05.026 · Cited by 863
Integrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863
Exosomes as a new frontier of cancer liquid biopsy
Yu, D., Li, Y., Wang, M., Gu, J., Xu, W., Cai, H., Fang, X., & Zhang, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01509-9 · Cited by 855
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
Roy, R., Yang, J., & Moses, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5556 · Cited by 854
Patra, K. C., Wang, Q., Bhaskar, P. T., Miller, L., Wang, Z., Wheaton, W., Chandel, N., Laakso, M., Muller, W. J., Allen, E. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.014 · Cited by 853
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Conservation of the human telomere sequence (TTAGGG)n among vertebrates.
Meyne, J., Ratliff, R. L., & Moyzis, R. K. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7049 · Cited by 843
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
MUC1: a multifaceted oncoprotein with a key role in cancer progression
Nath, S., & Mukherjee, P. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.02.007 · Cited by 837
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Physiology and pathophysiology of matrix metalloproteases
Klein, T., & Bischoff, R. (2011) · Amino Acids · doi:10.1007/s00726-010-0689-x · Cited by 828
p53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 826
Purification of a Human Prostate Specific Antigen
Wang, M. C., Valenzuela, L. A., Murphy, G. P., & Chu, T. M. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.100 · Cited by 825
Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001451 · Cited by 821
Ratiometric optical nanoprobes enable accurate molecular detection and imaging
Huang, X., Song, J., Yung, B. C., Huang, X., Xiong, Y., & Chen, X. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00612h · Cited by 820
Microbes, Microbiota, and Colon Cancer
Sears, C. L., & Garrett, W. S. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.007 · Cited by 818
NF- B as a Critical Link Between Inflammation and Cancer
Karin, M. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000141 · Cited by 816
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer
Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T. W. M., Miriyala, S., Lin, Y., Yao, J., Shi, J., Kang, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.022 · Cited by 804
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 800
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Senescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Helicobacter pylori-induced gastric inflammation and gastric cancer
Wang, F., Meng, W., Wang, B., & Qiao, L. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.08.016 · Cited by 793
The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer?
Brabletz, S., & Brabletz, T. (2010) · EMBO reports · doi:10.1038/embor.2010.117 · Cited by 793
Crystal structure of the human glucose transporter GLUT1
Deng, D., Xu, C., Sun, P., Wu, J., Yan, C., Hu, M., & Yan, N. (2014) · Nature · doi:10.1038/nature13306 · Cited by 777
Au Yeung, C. L., Co, N.-N., Tsuruga, T., Yeung, T.-L., Kwan, S.-Y., Leung, C. S., Li, Y., Lu, E. S., Kwan, K., Wong, K.-K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11150 · Cited by 774
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01688 · Cited by 769
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer
Schmalhofer, O., Brabletz, S., & Brabletz, T. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9179-y · Cited by 765
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30436-8 · Cited by 751
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
Grunnet, M., & Sorensen, J. B. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.012 · Cited by 750
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene
Christofori, G., & Semb, H. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01343-7 · Cited by 742
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.012 · Cited by 740
Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances
Huang, H. (2018) · Sensors · doi:10.3390/s18103249 · Cited by 739
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 733
The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression
Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0846 · Cited by 726
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716
Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates
Egan, D. F., Chun, M. G. H., Vamos, M., Zou, H., Rong, J., Miller, C. J., Lou, H. J., Raveendra-Panickar, D., Yang, C.-C., Sheffler, D. J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.031 · Cited by 715
Ansieau, S., Bastid, J., Doreau, A., Morel, A.-P., Bouchet, B. P., Thomas, C., Fauvet, F., Puisieux, I., Doglioni, C., Piccinin, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.005 · Cited by 715
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Analysis of DNA methylation in cancer: location revisited
Koch, A., Joosten, S. C., Feng, Z., de Ruijter, T. C., Draht, M. X., Melotte, V., Smits, K. M., Veeck, J., Herman, J. G., Van Neste, L., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0004-4 · Cited by 710
Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota
Ferreira, R. M., Pereira-Marques, J., Pinto-Ribeiro, I., Costa, J. L., Carneiro, F., Machado, J. C., & Figueiredo, C. (2018) · Gut · doi:10.1136/gutjnl-2017-314205 · Cited by 697
Strategies for Colorectal Cancer Screening
Ladabaum, U., Dominitz, J. A., Kahi, C., & Schoen, R. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.06.043 · Cited by 696
The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update
Siddiqui, W. A., Ahad, A., & Ahsan, H. (2015) · Archives of Toxicology · doi:10.1007/s00204-014-1448-7 · Cited by 696
Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01035 · Cited by 694
Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686
Application of exosomes as liquid biopsy in clinical diagnosis
Zhou, B., Xu, K., Zheng, X., Chen, T., Wang, J., Song, Y., Shao, Y., & Zheng, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00258-9 · Cited by 685
Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0070 · Cited by 676
Kim, J.-W., Gao, P., Liu, Y.-C., Semenza, G. L., & Dang, C. V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00440-07 · Cited by 658
Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 655
Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Winer, A., Adams, S., & Mignatti, P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0646 · Cited by 651
Hatta, K., & Takeichi, M. (1986) · Nature · doi:10.1038/320447a0 · Cited by 646
Scher, H. I., Lu, D., Schreiber, N. A., Louw, J., Graf, R. P., Vargas, H. A., Johnson, A., Jendrisak, A., Bambury, R., Danila, D., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1828 · Cited by 641
�ber den Stoffwechsel der Carcinomzelle
Warburg, O. (1924) · Die Naturwissenschaften · doi:10.1007/bf01504608 · Cited by 631
The Microbiota of Breast Tissue and Its Association with Breast Cancer
Urbaniak, C., Gloor, G. B., Brackstone, M., Scott, L., Tangney, M., & Reid, G. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.01235-16 · Cited by 625
Rustin, G. J. S., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G., Jakobsen, A., Sagae, S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182070f17 · Cited by 625
The angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 625
Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death
Ofengeim, D., & Yuan, J. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3683 · Cited by 621
de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F. M., Schaafsma, H. E., Debruyne, F. M. J., & Isaacs, W. B. (1992) · PubMed · Cited by 611
ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Zhang, P., Sun, Y., & Ma, L. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006048 · Cited by 611
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression
Seifert, L., Werba, G., Tiwari, S., Giao Ly, N. N., Alothman, S., Alqunaibit, D., Avanzi, A., Barilla, R., Daley, D., Greco, S. H., et al. (2016) · Nature · doi:10.1038/nature17403 · Cited by 611
Del Gaizo Moore, V., Brown, J. R., Certo, M., Love, T. M., Novina, C. D., & Letai, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 608
Circulating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., et al. (2019) · Liver International · doi:10.1111/liv.14223 · Cited by 597
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models
Sarkar, S., Perlstein, E. O., Imarisio, S., Pineau, S., Cordenier, A., Maglathlin, R. L., Webster, J. A., Lewis, T. A., O'Kane, C. J., Schreiber, S. L., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio883 · Cited by 596
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
RNA sequencing: new technologies and applications in cancer research
Hong, M., Tao, S., Zhang, L., Diao, L.-T., Huang, X., Huang, S., Xie, S.-J., Xiao, Z.-D., & Zhang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01005-x · Cited by 596
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Cadherin Switch in Tumor Progression
HAZAN, R. B., QIAO, R., KEREN, R., BADANO, I., & SUYAMA, K. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.016 · Cited by 595
Wieman, H. L., Wofford, J. A., & Rathmell, J. C. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-07-0593 · Cited by 593
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Letai, A. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2297 · Cited by 580
(1990) · PubMed · Cited by 579
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 563
Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis
Zhang, H., Deng, T., Liu, R., Bai, M., Zhou, L., Wang, X., Li, S., Wang, X., Yang, H., Li, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15016 · Cited by 562
p53 In tumour pathology: Can we trust immunohistochemistry?—revisited!
Hall, P. A., & Lane, D. P. (1994) · The Journal of Pathology · doi:10.1002/path.1711720103 · Cited by 561
Biomarker development in the precision medicine era: lung cancer as a case study
Vargas, A. J., & Harris, C. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.56 · Cited by 556
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
MUC1, The Renaissance Molecule
Gendler, S. J. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1011379725811 · Cited by 552
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551
Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
Shah, P. P., Donahue, G., Otte, G. L., Capell, B. C., Nelson, D. M., Cao, K., Aggarwala, V., Cruickshanks, H. A., Rai, T. S., McBryan, T., et al. (2013) · Genes & Development · doi:10.1101/gad.223834.113 · Cited by 550
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Zucker, S., Cao, J., & Chen, W.-T. (2000) · Oncogene · doi:10.1038/sj.onc.1204097 · Cited by 550
Targeting glutamine metabolism as a therapeutic strategy for cancer
Jin, J., Byun, J.-K., Choi, Y.-K., & Park, K.-G. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00971-9 · Cited by 550
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
The role of nuclear lamin B1 in cell proliferation and senescence
Shimi, T., Butin-Israeli, V., Adam, S. A., Hamanaka, R. B., Goldman, A. E., Lucas, C. A., Shumaker, D. K., Kosak, S. T., Chandel, N. S., & Goldman, R. D. (2011) · Genes & Development · doi:10.1101/gad.179515.111 · Cited by 547
Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein
Cao, Y., & Klionsky, D. J. (2007) · Cell Research · doi:10.1038/cr.2007.78 · Cited by 541
Gruenbaum, Y., & Foisner, R. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034115 · Cited by 541
Worby, C. A., & Dixon, J. E. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-082411-113907 · Cited by 535
de Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Curran, S., & Murray, G. I. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00156-8 · Cited by 531
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., & Asada, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5270 · Cited by 530
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
Camarda, R., Zhou, A. Y., Kohnz, R. A., Balakrishnan, S., Mahieu, C., Anderton, B., Eyob, H., Kajimura, S., Tward, A., Krings, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4055 · Cited by 528
Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
Capper, D., Weißert, S., Balss, J., Habel, A., Meyer, J., Jäger, D., Ackermann, U., Tessmer, C., Korshunov, A., Zentgraf, H., et al. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00352.x · Cited by 526
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Ntziachristos, P., Tsirigos, A., Vlierberghe, P. V., Nedjic, J., Trimarchi, T., Flaherty, M. S., Ferres-Marco, D., da Ros, V., Tang, Z., Siegle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2651 · Cited by 526
Non-redundant functions of EMT transcription factors
Stemmler, M. P., Eccles, R. L., Brabletz, S., & Brabletz, T. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0196-y · Cited by 524
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness
Sánchez-Tilló, E., Liu, Y., de Barrios, O., Siles, L., Fanlo, L., Cuatrecasas, M., Darling, D. S., Dean, D. C., Castells, A., & Postigo, A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1122-2 · Cited by 518
Ma, P. C., Kijima, T., Maulik, G., Fox, E. A., Sattler, M., Griffin, J. D., Johnson, B. E., & Salgia, R. (2003) · PubMed · Cited by 516
Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies
Solomon, V. R., & Lee, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.063 · Cited by 516
Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515
Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia
Montesinos, P., Recher, C., Vives, S., Zarzycka, E., Wang, J., Bertani, G., Heuser, M., Calado, R. T., Schuh, A. C., Yeh, S.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117344 · Cited by 514
Anticancer therapy targeting the apoptotic pathway
Hu, W., & Kavanagh, J. J. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01277-4 · Cited by 510
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
Zhu, A. X., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3836 · Cited by 509
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
Yamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
Fischer, T., Stone, R. M., DeAngelo, D. J., Galinsky, I., Estey, E., Lanza, C., Fox, E., Ehninger, G., Feldman, E. J., Schiller, G. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9678 · Cited by 504
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Epigenetic Therapies for Cancer
Bates, S. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1805035 · Cited by 493
Koo, G.-B., Morgan, M. J., Lee, D.-G., Kim, W.-J., Yoon, J.-H., Koo, J. S., Kim, S. I., Kim, S. J., Son, M. K., Hong, S. S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.56 · Cited by 491
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
The role of the ZEB family of transcription factors in development and disease
Vandewalle, C., Van Roy, F., & Berx, G. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8465-8 · Cited by 486
Beyond the margins: real-time detection of cancer using targeted fluorophores
Zhang, R. R., Schroeder, A. B., Grudzinski, J. J., Rosenthal, E. L., Warram, J. M., Pinchuk, A. N., Eliceiri, K. W., Kuo, J. S., & Weichert, J. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.212 · Cited by 485
Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancer
Murray, G. I., Duncan, M. E., O'Neil, P., Melvin, W. T., & Fothergill, J. E. (1996) · Nature Medicine · doi:10.1038/nm0496–461 · Cited by 481
Demonstration of a New Protein Fraction in Serum from the Human Fetus
Bergstrand, C. G., & Czar, B. (1956) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365515609049266 · Cited by 476
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Yen, K., Travins, J., Wang, F., David, M. D., Artin, E., Straley, K., Padyana, A., Gross, S., DeLaBarre, B., Tobin, E., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1034 · Cited by 471
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Smolarz, B., Łukasiewicz, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052049 · Cited by 259
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Metadata
- Authors
- Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-05-20
- Volume
- 9
- Issue
- 1
- Pages
- 132-132
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4397293886
- Cited by
- 720
- References
- 1,264
- FWCI
- 109.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.